{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:44:09Z","timestamp":1766087049352,"version":"build-2065373602"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jaad.2015.05.041","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T01:34:19Z","timestamp":1445477659000},"page":"759-767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Human papillomavirus vaccine trials and tribulations"],"prefix":"10.1016","volume":"73","author":[{"given":"Nancy S.","family":"Handler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc Z.","family":"Handler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomir","family":"Majewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.05.041_bib1","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2015.05.041_bib2","unstructured":"Centers for Disease Control and Prevention website. HPV vaccine information for clinicians - fact sheet. Available at: http:\/\/www.cdc.gov\/std\/hpv\/stdfact-hpv-vaccine-hcp.htm. Accessed July 25, 2015."},{"issue":"60","key":"10.1016\/j.jaad.2015.05.041_bib3","first-page":"277","article-title":"Cancer statistics","volume":"2010","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jaad.2015.05.041_bib4","first-page":"258","article-title":"Human papillomavirus\u2013associated cancers - United States, 2004-2008","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2015.05.041_bib5","unstructured":"Centers for Disease Control and Prevention website. Cervical cancer statistics. Available at: http:\/\/www.cdc.gov\/cancer\/cervical\/statistics\/index.htm. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10900-014-9950-7","article-title":"HPV vaccination completion and compliance with recommended dosing intervals among female and male adolescents in an inner-city community health center","volume":"40","author":"Wilson","year":"2015","journal-title":"J Community Health"},{"key":"10.1016\/j.jaad.2015.05.041_bib7","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaad.2015.05.041_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.canep.2014.09.003","article-title":"Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China)","volume":"38","author":"Serrano","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jaad.2015.05.041_bib9","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jaad.2015.05.041_bib10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1001\/jama.2014.12274","article-title":"Use of HPV vaccine in males and females","volume":"312","author":"Cifu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2015.05.041_bib11","unstructured":"American Cancer Society website. How much do the HPV vaccines cost? Are they covered by health insurance plans? Available at: http:\/\/www.org\/cancer\/cancercauses\/othercarcinogens\/infectiousagents\/hpv\/humanpapillomavirusandhpvvaccinesfaq\/hpv-faq-vaccine-cost. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib12","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1185\/03007990802281671","article-title":"Five-year routine cervical cancer screening rates and intervals in a US health plan","volume":"24","author":"Schabert","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaad.2015.05.041_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/cncr.23207","article-title":"Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004","volume":"112","author":"Ekwueme","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2015.05.041_bib14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jpepsy\/jsp108","article-title":"Factors influencing familial decision-making regarding human papillomavirus vaccination","volume":"35","author":"Gamble","year":"2010","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.jaad.2015.05.041_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajog.2004.01.042","article-title":"The health care costs of cervical human papillomavirus\u2013related disease","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jaad.2015.05.041_bib16","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":"Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States","volume":"30","author":"Chesson","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2015.05.041_bib17","doi-asserted-by":"crossref","first-page":"e1001147","DOI":"10.1371\/journal.pmed.1001147","article-title":"Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models","volume":"8","author":"Bogaards","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaad.2015.05.041_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.AOG.0000266984.23445.9c","article-title":"Sociodemographic factors associated with high-risk human papillomavirus infection","volume":"110","author":"Kahn","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jaad.2015.05.041_bib19","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2015.05.041_bib20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnci\/djn019","article-title":"Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination","volume":"100","author":"Goldhaber-Fiebert","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2015.05.041_bib21","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.ejca.2010.06.016","article-title":"Cost-effectiveness of human papillomavirus vaccination and screening in Spain","volume":"46","author":"Diaz","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2015.05.041_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/LGT.0b013e31823cde2f","article-title":"A cost-effectiveness analysis of anal cancer screening in HIV-positive women","volume":"16","author":"Lazenby","year":"2012","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jaad.2015.05.041_bib23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/QAD.0000000000000160","article-title":"High-resolution anoscopy screening of HIV-positive MSM: longitudinal results from a pilot study","volume":"28","author":"Dalla Pria","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2015.05.041_bib24","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jaad.2014.06.045","article-title":"Anal Pap smears and anal cancer: what dermatologists should know","volume":"71","author":"Liszewski","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.05.041_bib25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0002-9343(00)00349-1","article-title":"Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men","volume":"108","author":"Goldie","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2015.05.041_bib26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.281.19.1822","article-title":"The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men","volume":"281","author":"Goldie","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2015.05.041_bib27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","article-title":"Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis","volume":"10","author":"Kim","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaad.2015.05.041_bib28","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.vaccine.2014.10.052","article-title":"Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia","volume":"32","author":"Deshmukh","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2015.05.041_bib29","doi-asserted-by":"crossref","first-page":"g7584","DOI":"10.1136\/bmj.g7584","article-title":"Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model","volume":"350","author":"Jit","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2015.05.041_bib30","unstructured":"European Medicines Agency website. Gardasil. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000703\/human_med_000805.jsp. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib31","unstructured":"European Medicines Agency website. Cervarix. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000721\/human_med_000694.jsp&mid=WC0b01ac058001d124. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib32","unstructured":"Fierce Vaccines website. Gardasil: new 2-dose schedule granted positive CHMP opinion for Europe's leading HPV vaccine. Lyon, France: Fiercevaccines; 2014. Available at: http:\/\/www.fiercevaccines.com\/press-releases\/gardasil-new-2-dose-schedule-granted-positive-chmp-opinion-europes-leading. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib33","unstructured":"US Department of Health and Human Services website. The Affordable Care Act and Immunization Department of Health and Human Services. Available at: http:\/\/www.hhs.gov\/opa\/affordable-care-act\/index.html. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib34","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males\u2014Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2015.05.041_bib35","unstructured":"US Department of Health and Human Services website. Patient protection and Affordable Care Act of 2010. Available at: http:\/\/www.hhs.gov\/healthcare\/rights\/index.html. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.vaccine.2014.11.032","article-title":"Factors associated with HPV awareness among mothers of low-income ethnic minority adolescent girls in Los Angeles","volume":"33","author":"Glenn","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2015.05.041_bib37","unstructured":"World Health Organization website. Countries using HPV vaccine. Available at: http:\/\/www.who.int\/immunization\/diseases\/hpv\/decision_implementation\/en\/. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2051013614557476","article-title":"Human papilloma virus vaccination: impact and recommendations across the world","volume":"3","author":"Bonanni","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.jaad.2015.05.041_bib39","unstructured":"South African Government News Agency website. HPV vaccination campaign to be rolled out in schools. Available at: http:\/\/www.sanews.gov.za\/south-africa\/hpv-vaccination-campaign-be-rolled-out-schools. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib40","unstructured":"Gavi the vaccine alliance website. GAVI funds vaccines to protect girls against cervical cancer. 2012. Available at: http:\/\/www.gavi.org\/library\/news\/press-releases\/2013\/gavi-funds-vaccines-to-protect-girls-against-cervical-cancer\/. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib41","unstructured":"Australian Government website. HPV school vaccination program. Available at: http:\/\/hpv.health.gov.au\/. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib42","unstructured":"Immunize BC website. HPV (human papillomavirus) one-time vaccine program for young women. Available at: http:\/\/immunizebc.ca\/sites\/default\/files\/graphics\/hpv_healthfile_imm_record_form_0.pdf. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib43","unstructured":"Ontario Ministry of Health and Long-Term Care website. Ontario's HPV vaccination program. Available at: http:\/\/www.health.gov.on.ca\/en\/ms\/hpv\/. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib44","unstructured":"Alberta Health Services website. Common questions about HPV. http:\/\/immunizealberta.ca\/i-need-know-more\/common-questions\/hpv. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib45","unstructured":"Public Health Agency of Canada website. Provincial and territorial immunization information. Available at: http:\/\/healthycanadians.gc.ca\/healthy-living-vie-saine\/immunization-immunisation\/children-enfants\/schedule-calendrier-eng.php. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib46","unstructured":"Austria Federal Ministry of Health. Available at: http:\/\/www.bmg.gv.at\/home\/Schwerpunkte\/Gesundheitsfoerderung_Praevention\/Impfen\/HPV_Impfung. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib47","unstructured":"European Cervical Cancer Association website. HPV vaccination across Europe. Available at: http:\/\/www.ecca.info\/fileadmin\/user_upload\/HPV_Vaccination\/ECCA_HPV_Vaccination_April_2009.pdf. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib48","first-page":"21","article-title":"Current status of human papillomavirus vaccination implementation in central and eastern Europe","volume":"22","author":"Seme","year":"2013","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.jaad.2015.05.041_bib49","unstructured":"Judy S-I. HPV: to vaccinate or not to vaccinate. Israel News Jerusalem, Israel: The Jerusalem Post; 2013."},{"key":"10.1016\/j.jaad.2015.05.041_bib50","first-page":"1382","article-title":"Progress toward implementation of human papillomavirus vaccination\u2014the Americas, 2006-2010","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2015.05.041_bib51","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.4161\/21645515.2014.969618","article-title":"Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation","volume":"10","author":"Larson","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaad.2015.05.041_bib52","first-page":"53","article-title":"Global Advisory Committee on Vaccine Safety, 11-12 December 2013","volume":"89","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jaad.2015.05.041_bib53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458508096868","article-title":"CNS demyelination and quadrivalent HPV vaccination","volume":"15","author":"Sutton","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaad.2015.05.041_bib54","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/jnnp.2010.214924","article-title":"Demyelinating disease and polyvalent human papilloma virus vaccination","volume":"82","author":"Chang","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaad.2015.05.041_bib55","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1212\/WNL.0b013e3181aa53bb","article-title":"Acute disseminated encephalomyelitis following vaccination against human papilloma virus","volume":"72","author":"Wildemann","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2015.05.041_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2015.05.041_bib57","unstructured":"Centers for Disease Control and Prevention website. Frequently asked questions about HPV vaccine safety. Available at: http:\/\/www.cdc.gov\/vaccinesafety\/Vaccines\/HPV\/hpv_faqs.html. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/aji.12151","article-title":"Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune\/inflammatory syndrome induced by adjuvants","volume":"70","author":"Colafrancesco","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.jaad.2015.05.041_bib59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jjco\/hyr173","article-title":"Safety and immunogenicity profile of human papillomavirus-16\/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh","volume":"42","author":"Khatun","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jaad.2015.05.041_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jpag.2013.04.002","article-title":"Counseling about the HPV vaccine: desexualize, educate, and advocate","volume":"26","author":"Grimes","year":"2013","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.jaad.2015.05.041_bib61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e3181b77906","article-title":"Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine","volume":"29","author":"Block","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2015.05.041_bib62","unstructured":"Centers for Disease Control and Prevention website. Summary of HPV adverse event reports published in JAMA. Available at: https:\/\/web.archive.org\/web\/20150317013226\/http:\/\/www.cdc.gov\/vaccinesafety\/Vaccines\/HPV\/jama.html. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib63","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2015.05.041_bib64","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jval.2012.02.012","article-title":"Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan","volume":"15","author":"Demarteau","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jaad.2015.05.041_bib65","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2015.05.041_bib66","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.05.041_bib67","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.05.041_bib68","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2015.05.041_bib69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2015.05.041_bib70","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2015.05.041_bib71","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2015.05.041_bib72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","article-title":"HPV vaccine: Cervarix","volume":"10","author":"Szarewski","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2015.05.041_bib73","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/erv.12.42","article-title":"Cervarix(R): a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types","volume":"11","author":"Szarewski","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jaad.2015.05.041_bib74","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.4161\/hv.34408","article-title":"Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus","volume":"10","author":"Herrin","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaad.2015.05.041_bib75","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix(R) and Gardasil(R) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaad.2015.05.041_bib76","doi-asserted-by":"crossref","first-page":"457204","DOI":"10.5402\/2011\/457204","article-title":"Next generation cancer protection: the bivalent HPV vaccine for females","volume":"2011","author":"Harper","year":"2011","journal-title":"ISRN Obstet Gynecol"},{"key":"10.1016\/j.jaad.2015.05.041_bib77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/hv.7.2.13690","article-title":"Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.jaad.2015.05.041_bib78","doi-asserted-by":"crossref","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women","volume":"8","author":"Luna","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2015.05.041_bib79","unstructured":"Centers for Disease Control and Prevention website. HPV vaccine - questions & answers. August 6, 2014. Available at: http:\/\/www.cdc.gov\/vaccines\/vpd-vac\/hpv\/vac-faqs.htm. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1071\/SH10001","article-title":"Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia","volume":"8","author":"Gertig","year":"2011","journal-title":"Sex Health"},{"key":"10.1016\/j.jaad.2015.05.041_bib81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vaccine.2014.10.045","article-title":"Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program","volume":"33","author":"Osborne","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2015.05.041_bib82","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1741-7015-9-104","article-title":"Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program","volume":"9","author":"Garland","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.jaad.2015.05.041_bib83","unstructured":"US Department of Health and Human Services, US Food and Drug Administration website. FDA approves Gardasil 9 for\u00a0prevention of certain cancers caused by five additional types of HPV. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm426485.htm. Accessed July 25, 2015."},{"key":"10.1016\/j.jaad.2015.05.041_bib84","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215017491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215017491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:35:05Z","timestamp":1759271705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215017491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0190962215017491"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.05.041","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccine trials and tribulations","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(15)02215-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}